These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 33521483)

  • 1. Essential statistical principles of clinical trials of pain treatments.
    Dworkin RH; Evans SR; Mbowe O; McDermott MP
    Pain Rep; 2021; 6(1):e863. PubMed ID: 33521483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.
    Ratitch B; Bell J; Mallinckrodt C; Bartlett JW; Goel N; Molenberghs G; O'Kelly M; Singh P; Lipkovich I
    Ther Innov Regul Sci; 2020 Mar; 54(2):324-341. PubMed ID: 32072573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients.
    Rai SN; Qian C; Pan J; Seth A; Srivastava DK; Bhatnagar A
    BMC Med Res Methodol; 2020 Aug; 20(1):220. PubMed ID: 32867708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficiencies in reporting of statistical methodology in recent randomized trials of nonpharmacologic pain treatments: ACTTION systematic review.
    Dworkin JD; McKeown A; Farrar JT; Gilron I; Hunsinger M; Kerns RD; McDermott MP; Rappaport BA; Turk DC; Dworkin RH; Gewandter JS
    J Clin Epidemiol; 2016 Apr; 72():56-65. PubMed ID: 26597977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Empirical Comparison of Statistical Methods for Missing Data in Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trials for Chronic Pain and Lipid-Lowering Products.
    Gnang J; Kim Y; Ren Y; Travis J; Kim Y
    Ther Innov Regul Sci; 2020 Nov; 54(6):1416-1427. PubMed ID: 32500449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A predictive probability interim design for phase II clinical trials with continuous endpoints.
    Liu M; Dressler EV
    Stat Med; 2018 May; 37(12):1960-1972. PubMed ID: 29611211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyzing multiple endpoints in a confirmatory randomized clinical trial-an approach that addresses stratification, missing values, baseline imbalance and multiplicity for strictly ordinal outcomes.
    Sun H; Kawaguchi A; Koch G
    Pharm Stat; 2017 Mar; 16(2):157-166. PubMed ID: 28074600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical analysis of clinical trials.
    Wassertheil-Smoller S; Kim MY
    Semin Nucl Med; 2010 Sep; 40(5):357-63. PubMed ID: 20674595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments.
    Boutron I; Moher D; Altman DG; Schulz KF; Ravaud P;
    Ann Intern Med; 2008 Feb; 148(4):W60-6. PubMed ID: 18283201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choosing estimands in clinical trials with missing data.
    Mallinckrodt C; Molenberghs G; Rathmann S
    Pharm Stat; 2017 Jan; 16(1):29-36. PubMed ID: 27492760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trials in medical rehabilitation research.
    Tate DG; Findley T; Dijkers M; Nobunaga AI; Karunas RB
    Am J Phys Med Rehabil; 1999; 78(5):486-99. PubMed ID: 10493460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.
    Ratitch B; Goel N; Mallinckrodt C; Bell J; Bartlett JW; Molenberghs G; Singh P; Lipkovich I; O'Kelly M
    Ther Innov Regul Sci; 2020 Mar; 54(2):370-384. PubMed ID: 32072586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation of clinical endpoints in trials of acute myeloid leukemia.
    Medeiros BC
    Leuk Res; 2018 May; 68():32-39. PubMed ID: 29524739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. General statistical design considerations of randomized clinical trials.
    Peduzzi P
    Prog Clin Biol Res; 1988; 264():61-70. PubMed ID: 3289035
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.